• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31Annual Meeting of the Society for Immunotherapy of Cancer, 2016.正在研发中的新型癌症免疫治疗药物：来自 2016 年癌症免疫治疗学会第 31 届年会相关项目的报告。
J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017.
2
Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.第 31 届癌症免疫治疗学会（SITC）年会要点，2016 年。
J Immunother Cancer. 2017 Jul 18;5(1):55. doi: 10.1186/s40425-017-0262-1.
3
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.第 25 届国际癌症生物治疗学会年会综述。
J Transl Med. 2011 May 12;9:60. doi: 10.1186/1479-5876-9-60.
4
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.2014年癌症免疫治疗进展：癌症免疫治疗协会第12届年会报告——2014年5月6 - 8日于德国美因茨召开
Hum Vaccin Immunother. 2014;10(10):3090-100. doi: 10.4161/hv.29767.
5
CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.2017年国际肿瘤免疫治疗学会年会：周年研讨会——第15届国际肿瘤免疫治疗学会年会报告
Hum Vaccin Immunother. 2017 Oct 3;13(10):2272-2279. doi: 10.1080/21645515.2017.1358327.
6
Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.癌症免疫和免疫治疗中的小鼠和人源化模型的挑战、见解和未来方向研讨会：来自癌症免疫治疗学会 2016 年年会相关项目的报告。
J Immunother Cancer. 2017 Sep 19;5(1):77. doi: 10.1186/s40425-017-0278-6.
7
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.免疫疗法联合治疗研讨会。癌症免疫治疗学会年会，2011 年 11 月 3 日，美国马里兰州贝塞斯达。
J Transl Med. 2012 May 28;10:108. doi: 10.1186/1479-5876-10-108.
8
Immunotherapy for the treatment of breast cancer.用于治疗乳腺癌的免疫疗法。
Curr Oncol Rep. 2015 Feb;17(2):5. doi: 10.1007/s11912-014-0426-9.
9
Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.癌症相关成纤维细胞靶向策略增强基于树突状细胞疫苗的抗肿瘤免疫反应。
Cancer Sci. 2015 Feb;106(2):134-42. doi: 10.1111/cas.12584. Epub 2015 Jan 16.
10
Recent advances in cancer immunotherapy with an emphasis on vaccines.癌症免疫疗法的最新进展，重点是疫苗。
Expert Rev Vaccines. 2009 Jan;8(1):25-8. doi: 10.1586/14760584.8.1.25.

引用本文的文献

1
Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity.辐射驱动三级淋巴结构重塑肿瘤微环境以实现协同抗肿瘤免疫。
Expert Rev Mol Med. 2024 Oct 23;26:e30. doi: 10.1017/erm.2024.27.
2
Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review.免疫疗法治疗皮肤黑色素瘤的当前趋势：综述
Dermatol Ther (Heidelb). 2021 Oct;11(5):1481-1496. doi: 10.1007/s13555-021-00583-z. Epub 2021 Aug 2.
3
Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.局部晚期和复发性/转移性头颈部鳞状细胞癌的免疫治疗进展及其与人类乳头瘤病毒的关系。
Front Immunol. 2021 Jul 8;12:652054. doi: 10.3389/fimmu.2021.652054. eCollection 2021.
4
New emerging targets in cancer immunotherapy: the role of VISTA.癌症免疫治疗中的新新兴靶点：VISTA 的作用。
ESMO Open. 2020 Jun;4(Suppl 3):e000683. doi: 10.1136/esmoopen-2020-000683.
5
Anti-neoplastic and immunomodulatory potency of co-treatment based on bovine lactoferrin and/or muramyl dipeptide in tumor-bearing mice.基于牛乳铁蛋白和/或胞壁酰二肽联合治疗对荷瘤小鼠的抗肿瘤和免疫调节效力。
Toxicol Res (Camb). 2020 Apr 24;9(2):137-147. doi: 10.1093/toxres/tfaa012. eCollection 2020 Apr.
6
T-cell trafficking plays an essential role in tumor immunity.T 细胞迁移在肿瘤免疫中起着至关重要的作用。
Lab Invest. 2019 Jan;99(1):85-92. doi: 10.1038/s41374-018-0124-6. Epub 2018 Oct 23.
7
DNA repair defects and implications for immunotherapy.DNA 修复缺陷及其对免疫治疗的影响。
J Clin Invest. 2018 Oct 1;128(10):4236-4242. doi: 10.1172/JCI122010.
8
Current status and future directions of cancer immunotherapy.癌症免疫疗法的现状与未来方向
J Cancer. 2018 Apr 19;9(10):1773-1781. doi: 10.7150/jca.24577. eCollection 2018.
9
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.皮肤黑色素瘤免疫治疗的近期成果与未来方向
Front Immunol. 2017 Dec 8;8:1617. doi: 10.3389/fimmu.2017.01617. eCollection 2017.

本文引用的文献

1
Elements of cancer immunity and the cancer-immune set point.癌症免疫的要素和癌症免疫基准。
Nature. 2017 Jan 18;541(7637):321-330. doi: 10.1038/nature21349.
2
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.阿替利珠单抗联合贝伐珠单抗增强转移性肾细胞癌的抗原特异性 T 细胞迁移。
Nat Commun. 2016 Aug 30;7:12624. doi: 10.1038/ncomms12624.
3
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.具有细胞内源性程序性死亡蛋白1（PD-1）检查点阻断功能的人嵌合抗原受体（CAR）T细胞可抵抗肿瘤介导的抑制作用。
J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.
4
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.抗程序性死亡蛋白1（PD-1）活性在恩杂鲁胺耐药前列腺癌中的早期证据。
Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547.
5
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).免疫逃避 PD-L1/PD-1 阻断：成功（或失败）的七个步骤。
Ann Oncol. 2016 Aug;27(8):1492-504. doi: 10.1093/annonc/mdw217. Epub 2016 May 20.
6
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.肿瘤部位CD103(+)树突状细胞祖细胞的扩增与激活增强了肿瘤对治疗性PD-L1和BRAF抑制的反应。
Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012.
7
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.MAP 激酶抑制与 PD-L1 检查点阻断联合促进 T 细胞和抗肿瘤活性。
Immunity. 2016 Mar 15;44(3):609-621. doi: 10.1016/j.immuni.2016.01.024. Epub 2016 Mar 2.
8
Haplotyping germline and cancer genomes with high-throughput linked-read sequencing.利用高通量连锁读长测序对种系和癌症基因组进行单倍型分型
Nat Biotechnol. 2016 Mar;34(3):303-11. doi: 10.1038/nbt.3432. Epub 2016 Feb 1.
9
ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.针对胶质母细胞瘤的靶向治疗的 ErbB2/HER2 特异性 NK 细胞。
J Natl Cancer Inst. 2015 Dec 6;108(5). doi: 10.1093/jnci/djv375. Print 2016 May.
10
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors.靶向间皮素的嵌合抗原受体：驱动T细胞作用于实体瘤。
Cancer Discov. 2016 Feb;6(2):133-46. doi: 10.1158/2159-8290.CD-15-0583. Epub 2015 Oct 26.

正在研发中的新型癌症免疫治疗药物：来自 2016 年癌症免疫治疗学会第 31 届年会相关项目的报告。

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31Annual Meeting of the Society for Immunotherapy of Cancer, 2016.

机构信息

Center for Cell Engineering; Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA.

Genentech, 1 DNA Way, South San Francisco, CA 94080 USA.

出版信息

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017.

DOI:10.1186/s40425-017-0253-2
PMID:28649381
原文链接:
https://pmc.ncbi.nlm.nih.gov/articles/PMC5477277/
Abstract

This report is a summary of 'New Cancer Immunotherapy Agents in Development' program, which took place in association with the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), on November 9, 2016 in National Harbor, Maryland. Presenters gave brief overviews of emerging clinical and pre-clinical immune-based agents and combinations, before participating in an extended panel discussion with multidisciplinary leaders, including members of the FDA, leading academic institutions and industrial drug developers, to consider topics relevant to the future of cancer immunotherapy.

摘要

本报告是 2016 年 11 月 9 日在马里兰州国家港湾举行的第 31 届癌症免疫治疗学会（SITC）年会期间“新型癌症免疫治疗药物研发”计划的总结。演讲者简要介绍了新兴的临床和临床前免疫药物及联合用药，随后参加了一个由多学科专家组成的扩展小组讨论，成员包括 FDA、领先学术机构和工业药物开发商，以讨论与癌症免疫治疗未来相关的议题。